Plain-English translation of NCT07383649 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called —an antiviral drug—combined with your standard breast cancer treatment. The study focuses on patients with breast cancer that has spread to the brain and who also have a cytomegalovirus (CMV) infection. Researchers want to see if treating the CMV infection might help slow or stop the brain tumors from growing.
Brain metastases are a serious complication of advanced breast cancer that is difficult to treat. Researchers have noticed that some patients with progressive brain tumors also have CMV infection, and they want to learn whether treating the viral infection with this medication could improve outcomes.
You likely qualify if…
You likely don't qualify if…
You would take tablets twice daily for 2 weeks at a higher dose, then twice daily for 4 more weeks at a lower dose, along with your regular cancer treatment. During this time, you'll have weekly blood tests during the first 2 weeks to check for side effects and viral clearance, then every 2 weeks during the second phase. You'll also have brain imaging scans every 2 months, quality-of-life questionnaires, and memory/thinking tests. The entire study lasts 24 months, with regular visits to your cancer care team.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States